Filing Flows › Prothena Corp Public (PRTA) › Guidance & outlook

Prothena Corp Public (PRTA) guidance and outlook

Prothena Corp Public's 10-Q filed Nov 5, 2026 makes 18 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 5, 2026

• Fueled by our deep scientific expertise built over decades of research, we are advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged.
• In the first half of 2026, we completed the Phase 1 clinical trial which successfully demonstrated a benign safety and tolerability profile, no immunogenicity, and dose-dependent pharmacokinetics and pharmacodynamic effects meeting our prespecified pharmacodynamic targets.
• If promising, we expect to advance our discovery and preclinical programs to clinical development.
• New target discovery will focus on areas where we can bring potential new therapies to patients expeditiously through our internal expertise and resources.
• In November 2025, we presented a poster titled Treatment with a Cell-Internalizing CYTOPE ® Targeting pTDP-43 Reduces Intraneuronal Pathology in a Mouse Model of ALS at Neuroscience 2025, hosted by the Society for Neuroscience (SfN) and subsequently presented encores at the 36 th International Symposium of ALS/MND 2025 and the 2026 European Network to Cure ALS (ENCALS).
• These results demonstrate the potential of our CYTOPE ® technology as a novel modality, enabling precise targeting of intracellular disease pathways.
• We plan to explore potential partnership interest to advance PRX012 and our preclinical PRX012-TfR (transferrin receptor) antibody programs.
• Initial preclinical studies on our surrogate Aβ-TfR antibody have demonstrated substantially increased brain exposure and facilitated rapid targeting of Aβ plaques in an APP/PS1 transgenic mouse model.
• We are developing a dual vaccine, PRX123, which concomitantly targets key epitopes within both the Aβ and tau proteins.
• Additionally, in order to develop and obtain regulatory approval for our potential products we will need to raise substantial additional capital.
• We expect to continue to finance future capital needs that exceed our existing cash and cash equivalents, payments pursuant to our agreements with Roche, BMS, and Novo Nordisk, and, to the extent necessary, other collaboration agreements with corporate partners, or other arrangements, and
• We cannot assume that such additional financings will be available on acceptable terms, if at all, and such financings may only be available on terms dilutive to our shareholders.

Prothena Corp Public's latest quarter

Questions

What does Prothena Corp Public expect?

Fueled by our deep scientific expertise built over decades of research, we are advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. In the first half of 2026, we completed the Phase 1 clinical trial which successfully demonstrated a benign safety and tolerability profile, no immunogenicity, and dose-dependent pharmacokinetics and pharmacodynamic effects meeting our prespecified pharmacodynamic targets. If promisin

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.